On November 10, IDEXX Laboratories fell 3.18% in Regular Trading, trading at $684.0375, with turnover of $49.9317 million.
Publicly available information around the move indicates no newly disclosed company-specific negative catalyst at that time; instead, the stock's earlier earnings-driven support appeared to moderate after a prior rally tied to third-quarter results and raised full-year guidance.
Earlier disclosures showed third-quarter comparable EPS of $3.96 versus market expectations of $3.73, with revenue of $1.21 billion versus the expected $1.19 billion. The company also lifted full-year comparable EPS growth guidance to 15% to 16% from 13% to 15% and raised revenue guidance to $4.74 billion-$4.77 billion from $4.70 billion-$4.75 billion. Additional commentary from analysts highlighted resilient pricing despite softer veterinary visit trends, but that backdrop does not point to a fresh negative trigger for this decline.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments